Tetrafluoroterephthalonitrile (TFTPN) is a highly reactive and versatile building block in organic synthesis. It is a white crystalline solid with a high melting point. TFTPN is commonly synthesized by the fluorination of terephthalonitrile using a variety of reagents and methods. It is an important precursor for the synthesis of various fluorinated polymers, pharmaceuticals, and electronic materials. TFTPN is highly reactive due to the presence of four fluorine atoms, which are electron-withdrawing and activate the aromatic ring for nucleophilic attack. It is studied for its potential applications in various fields, including polymer science, medicinal chemistry, and materials science. Its high reactivity allows for the synthesis of a wide range of functionalized derivatives with unique properties, such as enhanced thermal stability, hydrophobicity, and dielectric constant.'
```
tetrafluoroterephthalonitrile: can cause contact dermatitis; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 15783 |
| CHEMBL ID | 3248223 |
| SCHEMBL ID | 57543 |
| MeSH ID | M0166241 |
| Synonym |
|---|
| k9nay7jk97 , |
| unii-k9nay7jk97 |
| 2,3,5,6-tetrafluoroterephthalonitrile |
| tetrafluoroterephthalodinitrile |
| nsc 97007 |
| einecs 217-397-3 |
| 1,4-dicyanotetrafluorobenzene |
| 2,3,5,6-tetrafluoro-1,4-benzenedicarbonitrile |
| 1,4-benzenedicarbonitrile, 2,3,5,6-tetrafluoro- |
| tetrafluoroterephthalonitrile |
| 2,5,6-tetrafluoroterephthalonitrile |
| nsc-97007 |
| nsc97007 |
| 2,5,6-tetrafluoro-1,4-benzenedicarbonitrile |
| wln: ncr bf cf ef ff dcn |
| diamond 2031 |
| terephthalonitrile, tetrafluoro- |
| 1835-49-0 |
| tetrafluoroterephthalonitrile, 99% |
| 2,3,5,6-tetrafluorobenzene-1,4-dicarbonitrile |
| AKOS005063551 |
| perfluoroterephthalonitrile |
| T1050 |
| A20998 |
| 1,4-dicyano-2,3,5,6-tetrafluorobenzene;2,3,5,6-tetrafluoro-4-benzenedicarbonitrile |
| STK731076 |
| FT-0633873 |
| AM84637 |
| 4-thiomorpholinepropanoicacid |
| CHEMBL3248223 |
| SCHEMBL57543 |
| 1,2,4,5-tetrafluoro-3,6-dicyanobenzene |
| tetrafluorobenzene-1,4-dicarbonitrile |
| AC-26104 |
| 1,4-dicyano-2,3,5,6-tetrafluorobenzene |
| DTXSID1075141 |
| mfcd00001776 |
| J-011756 |
| PS-10080 |
| YSZC139 |
| tetrafluoro-p-dicyanobenzene |
| CS-W010493 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "8% reduction at 100 mg/kg), six compounds, dosed at 50 mg/kg, produced reductions in inflammation comparable to this standard." | ( Synthesis and antiinflammatory evaluation of substituted isophthalonitriles, trimesonitriles, benzonitriles, and terephthalonitriles. Battershell, RD; Goble, PH; Heilman, WP; Magee, TA; Pyne, WJ, 1978) | 0.26 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1133368 | Antiinflammatory activity in Long Evans rat assessed as reduction of carrageenan-induced pedal edema at 50 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 3 hrs relative to control | 1978 | Journal of medicinal chemistry, Sep, Volume: 21, Issue:9 | Synthesis and antiinflammatory evaluation of substituted isophthalonitriles, trimesonitriles, benzonitriles, and terephthalonitriles. |
| AID1133373 | Toxicity in mouse assessed as overt effects | 1978 | Journal of medicinal chemistry, Sep, Volume: 21, Issue:9 | Synthesis and antiinflammatory evaluation of substituted isophthalonitriles, trimesonitriles, benzonitriles, and terephthalonitriles. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.39) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (20.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||